DocWire News Editors

DocwireNews

Immunotherapy in cancer has revolutionized cancer treatment and has become a universal answer to the question &ldquo;how can we treat cancer?&rdquo;&nbsp;However, checkpoint inhibitors&nbsp;(CPIs),&nbsp;a type of immunotherapy,&nbsp;is associated with a new group of immune-related adverse events (irAEs) in almost any organ system. In a recent study published in&nbsp;Nature Reviews Rheumatology, researchers outline these new questions and unmet needs that rheumatologists might be dealing with more.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Our new <a href="https://twitter.com/hashtag/Review?src=hash&amp;ref_src=twsrc%5Etfw">#Review</a> on Rheumatic immune-related adverse events from cancer immunotherapy is online now! <a href="https://twitter.com/LCalabreseDO?ref_src=twsrc%5Etfw">@LCalabreseDO</a> Check it out at <a href="https://t.co/eA0IpaAQ4o">https://t.co/eA0IpaAQ4o</a> <a href="https://t.co/u4GctmV37d">pic.twitter.com/u4GctmV37d</a>
&mdash; NatRevRheumatol (@NatRevRheumatol) <a href="https://twitter.com/NatRevRheumatol/status/1035970570909900800?ref_src=twsrc%5Etfw">September 1, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>According to the review, treatment of&nbsp;irAEs&nbsp;often requires immunosuppression with glucocorticoids, which are sometimes administered&nbsp;with conventional synthetic or biologic disease-modifying drugs.&nbsp;And although&nbsp;rheumatoid&nbsp;irAEs&nbsp;are not as common as traditional&nbsp;irAEs, they are&nbsp;underdiagnosed and less well recognized&nbsp;which is half of the problem.&nbsp;The review also states that rheumatic&nbsp;irAEs&nbsp;seem to be nosologically distinct, occurring both early and late in response to CPI therapy. To make matters worse,&nbsp;a substantial proportion of them are chronic, persisting even after cessation of CPI therapy.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
irAEs from cancer IMMUNOTHERAPY should be the domain for RHEUMATOLOGISTS to lead in both research and care &ndash; WE DO MULTISYTEM AUTOIMMUNITY for a living!!!!! <a href="https://twitter.com/jhrheumatology?ref_src=twsrc%5Etfw">@jhrheumatology</a> <a href="https://twitter.com/CleClinicMD?ref_src=twsrc%5Etfw">@CleClinicMD</a> <a href="https://twitter.com/HealioRheum?ref_src=twsrc%5Etfw">@HealioRheum</a> <a href="https://twitter.com/HealioRheum?ref_src=twsrc%5Etfw">@HealioRheum</a> <a href="https://twitter.com/hashtag/CleClinicCancer?src=hash&amp;ref_src=twsrc%5Etfw">#CleClinicCancer</a> <a href="https://twitter.com/hashtag/immunotherapy?src=hash&amp;ref_src=twsrc%5Etfw">#immunotherapy</a> <a href="https://twitter.com/MikkaelSekeres?ref_src=twsrc%5Etfw">@MikkaelSekeres</a> <a href="https://twitter.com/VamsiVelcheti?ref_src=twsrc%5Etfw">@VamsiVelcheti</a> <a href="https://t.co/ltH5w8JzzY">https://t.co/ltH5w8JzzY</a>
&mdash; Leonard Calabrese (@LCalabreseDO) <a href="https://twitter.com/LCalabreseDO/status/1035982570104791041?ref_src=twsrc%5Etfw">September 1, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Rheumatic related adverse events seem to be nosologically distinct, occurring both early and late in response to Check points inh (CPI) therapy. A proportion of them are chronic, persisting even after cessation of CPI therapy. <a href="https://twitter.com/LCalabreseDO?ref_src=twsrc%5Etfw">@LCalabreseDO</a> <a href="https://twitter.com/CCalabreseDO?ref_src=twsrc%5Etfw">@CCalabreseDO</a> <a href="https://t.co/DBq61Gk740">https://t.co/DBq61Gk740</a>
&mdash; Reumatolog&iacute;a Clinic (@Reumaclinic) <a href="https://twitter.com/Reumaclinic/status/1036500878138716160?ref_src=twsrc%5Etfw">September 3, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&ldquo;Rheumatologists must be prepared for&nbsp;irAEs&nbsp;and contribute to inter-professional teams in managing immunotherapy for patients with cancer,&rdquo; the researchers concluded.&nbsp;Check out&nbsp;an article on&nbsp;if a specific&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/systemic-sclerosis-serum-biomarker/">serum biomarker could positively impact patient survival</a>.&nbsp;SOURCE:&nbsp;<a href="https://www.nature.com/articles/s41584-018-0074-9">Nature Reviews Rheumatology&nbsp;</a>

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Cancer Immunotherapy: Knowing the Immune-related Adverse Events

Rheumatology

Immunotherapy in cancer has revolutionized cancer treatment and has become a universal answer to the question “how can we treat cancer?” However, checkpoint ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe